Press release content from Business Wire. The AP news staff was not involved in its creation.
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
May 3, 2021 GMT
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
PARIS (BUSINESS WIRE) May 3, 2021
Regulatory News:
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that
Liberia: 350 People Benefit from Free Eye Surgery in Bong County Liberia: 350 People Benefit from Free Eye Surgery in Bong County
More than 350 people in Bong benefited from the week-long free eye surgery
Salala, Bong County – No fewer than 350 people in Bong County have benefitted from the latest phase of the Samaritan’s Purse sponsored Free Eye Surgery Outreach program; a program aimed at improving the quality of life of the beneficiaries by restoring their vision through surgical intervention.
It’s a partnership with the New Sight Eye Center and the Ministry of Health.
Speaking at the flag-off of a week-long program, Bong County Health Officer, Dr. Jonathan Flomo, said that sight restoration and prevention of blindness have become the most considered and cost-effective interventionist strategies in the healthcare system.
SIFI Initiates Patient Enrollment in Phase II Trial evaluating Pro-ocular in Dry Eye Disease
ProGIFT is a 3 arms, multicenter, randomized, double-masked clinical trial in Italy.
CATANIA, Italy, April 27, 2021 /PRNewswire/ SIFI announced today the enrollment of the first patients in the ProGIFT trial (NCT04645446), which aims at evaluating the safety and efficacy of Pro-ocular, a progesterone based topical gel in patients with Dry Eye Disease (DED). ProGIFT (NCT04645446) is a multicenter, randomized, double-masked, placebo-controlled Phase II clinical trial comparing different concentrations of Pro-ocular (1% and 0.5%)
versus placebo. The trial involves 4 leading ophthalmic centers in Italy specialized on disorders of the ocular surface and is expected to recruit 105 participants.
16th Annual Readers Choice Contest
Welcome to Union Recorder 16th Annual Reader s Choice Contest Nominations phase!.
The Union Recorder
determined to be fraudulent.
How to get started.
Step 1 - Getting an account
If you haven t voted online before, you ll need to set yourself up with a FREE account. Fill out and submit the registration form. You ll be sent an email to authenticate your account. After you have authenticated your account you can log in and start the nomination process.
To submit your nominations,
Step 2 - The nomination process
(Nominations will take place April 24 - May 4, 2021)
ONLY ONE BALLOT PER REGISTERED VOTER is allowed. Please see CONTEST RULES.
Офтальмологический центр «Глазка» подарит детям призы за рисунки | НГС ngs.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ngs.ru Daily Mail and Mail on Sunday newspapers.